Bushra Gorsi1, Edgar Hernandez1, Marvin Barry Moore1, Mika Moriwaki2, Clement Y Chow3, Emily Coelho3, Elaine Taylor4, Claire Lu4, Amanda Walker4, Philippe Touraine5, Lawrence M Nelson6, Amber R Cooper7, Elaine R Mardis8, Aleksander Rajkovic9, Mark Yandell1, Corrine K Welt2. 1. Utah Center for Genetic Discovery, Department of Human Genetics, University of Utah, Salt Lake City, UT, USA. 2. Division of Endocrinology, Metabolism and Diabetes, University of Utah, Salt Lake City, UT, USA. 3. Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA. 4. University of Utah School of Medicine, Salt Lake City, UT, USA. 5. Sorbonne Universite, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Service d'Endocrinologie et Médecine de la Reproduction, Centre de Maladies Endocriniennes Rares de la Croissance et du Développement, Centre de Pathologies Gynécologiques Rares, Paris, France. 6. Conover Foundation, McLean, VA, USA. 7. Vios Fertility Institute, St. Louis, MO, USA. 8. Institute for Genomic Medicine, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, OH, USA. 9. Department of Pathology, University of California San Francisco School of Medicine, San Francisco, CA, USA.
Abstract
CONTEXT: A genetic etiology likely accounts for the majority of unexplained primary ovarian insufficiency (POI). OBJECTIVE: We hypothesized that heterozygous rare variants and variants in enhanced categories are associated with POI. DESIGN: The study was an observational study. SETTING: Subjects were recruited at academic institutions. PATIENTS: Subjects from Boston (n = 98), the National Institutes of Health and Washington University (n = 98), Pittsburgh (n = 20), Italy (n = 43), and France (n = 32) were diagnosed with POI (amenorrhea with an elevated follicle-stimulating hormone level). Controls were recruited for health in old age or were from the 1000 Genomes Project (total n = 233). INTERVENTION: We performed whole exome sequencing (WES), and data were analyzed using a rare variant scoring method and a Bayes factor-based framework for identifying genes harboring pathogenic variants. We performed functional studies on identified genes that were not previously implicated in POI in a D. melanogaster model. MAIN OUTCOME: Genes with rare pathogenic variants and gene sets with increased burden of deleterious variants were identified. RESULTS: Candidate heterozygous variants were identified in known genes and genes with functional evidence. Gene sets with increased burden of deleterious alleles included the categories transcription and translation, DNA damage and repair, meiosis and cell division. Variants were found in novel genes from the enhanced categories. Functional evidence supported 7 new risk genes for POI (USP36, VCP, WDR33, PIWIL3, NPM2, LLGL1, and BOD1L1). CONCLUSIONS: Candidate causative variants were identified through WES in women with POI. Aggregating clinical data and genetic risk with a categorical approach may expand the genetic architecture of heterozygous rare gene variants causing risk for POI.
CONTEXT: A genetic etiology likely accounts for the majority of unexplained primary ovarian insufficiency (POI). OBJECTIVE: We hypothesized that heterozygous rare variants and variants in enhanced categories are associated with POI. DESIGN: The study was an observational study. SETTING: Subjects were recruited at academic institutions. PATIENTS: Subjects from Boston (n = 98), the National Institutes of Health and Washington University (n = 98), Pittsburgh (n = 20), Italy (n = 43), and France (n = 32) were diagnosed with POI (amenorrhea with an elevated follicle-stimulating hormone level). Controls were recruited for health in old age or were from the 1000 Genomes Project (total n = 233). INTERVENTION: We performed whole exome sequencing (WES), and data were analyzed using a rare variant scoring method and a Bayes factor-based framework for identifying genes harboring pathogenic variants. We performed functional studies on identified genes that were not previously implicated in POI in a D. melanogaster model. MAIN OUTCOME: Genes with rare pathogenic variants and gene sets with increased burden of deleterious variants were identified. RESULTS: Candidate heterozygous variants were identified in known genes and genes with functional evidence. Gene sets with increased burden of deleterious alleles included the categories transcription and translation, DNA damage and repair, meiosis and cell division. Variants were found in novel genes from the enhanced categories. Functional evidence supported 7 new risk genes for POI (USP36, VCP, WDR33, PIWIL3, NPM2, LLGL1, and BOD1L1). CONCLUSIONS: Candidate causative variants were identified through WES in women with POI. Aggregating clinical data and genetic risk with a categorical approach may expand the genetic architecture of heterozygous rare gene variants causing risk for POI.
Authors: Michelle A Wood-Trageser; Fatih Gurbuz; Svetlana A Yatsenko; Elizabeth P Jeffries; L Damla Kotan; Urvashi Surti; Deborah M Ketterer; Jelena Matic; Jacqueline Chipkin; Huaiyang Jiang; Michael A Trakselis; A Kemal Topaloglu; Aleksandar Rajkovic Journal: Am J Hum Genet Date: 2014-12-04 Impact factor: 11.025
Authors: Karin V Fuentes Fajardo; David Adams; Christopher E Mason; Murat Sincan; Cynthia Tifft; Camilo Toro; Cornelius F Boerkoel; William Gahl; Thomas Markello Journal: Hum Mutat Date: 2012-03-05 Impact factor: 4.878
Authors: T Shindo; H Kurihara; K Kuno; H Yokoyama; T Wada; Y Kurihara; T Imai; Y Wang; M Ogata; H Nishimatsu; N Moriyama; Y Oh-hashi; H Morita; T Ishikawa; R Nagai; Y Yazaki; K Matsushima Journal: J Clin Invest Date: 2000-05 Impact factor: 14.808
Authors: W Vegetti; M Grazia Tibiletti; G Testa; F Alagna; E Castoldi; M Taborelli; T Motta; P F Bolis; L Dalprà; P G Crosignani Journal: Hum Reprod Date: 1998-07 Impact factor: 6.918
Authors: Stephanie A Pangas; Carolina J Jorgez; Mai Tran; Julio Agno; Xiaohui Li; Chester W Brown; T Rajendra Kumar; Martin M Matzuk Journal: Mol Endocrinol Date: 2007-07-03
Authors: Richard A Kerber; Elizabeth O'Brien; Kenneth M Boucher; Ken R Smith; Richard M Cawthon Journal: PLoS One Date: 2012-04-10 Impact factor: 3.240
Authors: R Morales; B Lledo; J A Ortiz; F M Lozano; E M Garcia; A Bernabeu; A Fuentes; R Bernabeu Journal: J Assist Reprod Genet Date: 2022-10-08 Impact factor: 3.357